Table 2. Univariate Cox regression analysis of RFS for different models of SNP rs3775291 and rs4833095 in 715 breast cancer patients.

Variables		HR (95%CI)	P
Age			0.60
	<50	1.00
	≥50	0.91 (0.65–1.29)
Menopausal status			0.87
	Premenopausal	1.00
	Postmenopausal	0.97 (0.69–1.37)
ER status			<0.01
	Negative	1.00
	Positive	0.50 (0.33–0.74)
PR status			0.01
	Negative	1.00
	Positive	0.60 (0.40–0.88)
HER2 status			<0.01
	Negative	1.00
	Positive	2.13 (1.36–3.33)
Lymph node status			<0.01
	Negative	1.00
	Positive	2.80 (1.87–4.19)
Tumor size(cm)			<0.01
	≤2	1.00
	>2	2.59 (1.73–3.86)
Chemotherapy			<0.01
	No	1.00
	Yes	3.34 (1.92–5.82)
Endocrine therapy			<0.01
	No	1.00
	Yes	0.51 (0.34–0.76)
TLR3 rs3775291:
Recessive model			<0.01
	AG+GG	1.00
	AA	2.06 (1.31–3.23)
Dominant model			0.31
	AG+AA	1.00
	GG	0.83 (0.59–1.18)
Co-dominant model			0.01
	GG	1.00
	AG	1.07 (0.73–1.56)	0.74
	AA	2.04 (1.24–3.35)	<0.01
TLR1 rs4833095:
Recessive model			0.06
	TC+CC	1.00
	TT	0.55 (0.30–1.01)
Dominant model			0.41
	TC+TT	1.00
	CC	1.16 (0.82–1.64)
Co-dominant model			0.16
	CC	1.00
	TC	0.97 (0.67–1.39)	0.85
	TT	0.54 (0.29–1.02)	0.06

ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2